Literature DB >> 14996719

Hypermethylation of a small CpGuanine-rich region correlates with loss of activator protein-2alpha expression during progression of breast cancer.

Donna B Douglas1, Yoshimitsu Akiyama, Hetty Carraway, Steven A Belinsky, Manel Esteller, Edward Gabrielson, Sigmund Weitzman, Trevor Williams, James G Herman, Stephen B Baylin.   

Abstract

The transcription factor activator protein-2alpha (AP-2alpha) has recently been implicated as a tumor suppressor protein that can be lost during tumor progression and that exhibits growth-inhibitory properties when overexpressed in cancer cell lines. We now demonstrate that hypermethylation of a discrete 5' region within a promoter CpG island of the gene is associated in breast cancer with the loss of AP-2alpha expression. Multiple CpG sites within the island become hypermethylated during breast cancer evolution. However, only hypermethylation of the most CpG-rich region, a small, approximately 300-bp area at the 3' end of exon 1, fully distinguishes neoplastic from normal breast tissue and correlates with transcriptional silencing. In cell culture, silenced AP-2alpha, associated with exon 1 hypermethylation, is re-expressed by 5-aza-2'deoxycytidine resulting in the restoration of a functional DNA sequence-specific binding protein. In vivo, as detected by a very sensitive nested PCR approach, methylation of the discrete AP-2alpha exon 1 region does not occur in normal breast epithelium and occurs in only 3 (16%) of 19 ductal carcinoma in situ (DCIS) lesions, but is present in 12 (75%) of 16 invasive breast tumors (P < 0.001; DCIS versus invasive cancers). Tumors unmethylated for this region expressed AP-2alpha protein throughout, whereas tumors with hypermethylation showed large areas of loss. Our studies then determine that hypermethylation of a small region of a CpG island correlates with silencing of AP-2alpha in breast cancer and suggest that inactivation of this gene could be a factor in, and a useful marker for, the progression of DCIS lesions.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14996719     DOI: 10.1158/0008-5472.can-0318-2

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  26 in total

1.  A computational genomics approach to identify cis-regulatory modules from chromatin immunoprecipitation microarray data--a case study using E2F1.

Authors:  Victor X Jin; Alina Rabinovich; Sharon L Squazzo; Roland Green; Peggy J Farnham
Journal:  Genome Res       Date:  2006-10-19       Impact factor: 9.043

2.  Hypoxia-induced Changes in SUMO Conjugation Affect Transcriptional Regulation Under Low Oxygen.

Authors:  Georgia Chachami; Nicolas Stankovic-Valentin; Angeliki Karagiota; Angeliki Basagianni; Uwe Plessmann; Henning Urlaub; Frauke Melchior; George Simos
Journal:  Mol Cell Proteomics       Date:  2019-03-29       Impact factor: 5.911

3.  Reversal of epigenetic silencing of AP-2alpha results in increased zinc uptake in DU-145 and LNCaP prostate cancer cells.

Authors:  Peter B Makhov; Konstantin V Golovine; Alexander Kutikov; Daniel J Canter; Vera A Rybko; Dmitry A Roshchin; Vsevolod B Matveev; Robert G Uzzo; Vladimir M Kolenko
Journal:  Carcinogenesis       Date:  2011-09-22       Impact factor: 4.944

4.  Aberrant CpG methylation of the TFAP2A gene constitutes a mechanism for loss of TFAP2A expression in human metastatic melanoma.

Authors:  Andrea R Hallberg; Sabine U Vorrink; Danielle R Hudachek; Kimberly Cramer-Morales; Mohammed M Milhem; Robert A Cornell; Frederick E Domann
Journal:  Epigenetics       Date:  2014-12       Impact factor: 4.528

5.  The MLL partial tandem duplication: evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular-targeted therapy.

Authors:  Susan P Whitman; Shujun Liu; Tamara Vukosavljevic; Laura J Rush; Li Yu; Chunhui Liu; Marko I Klisovic; Kati Maharry; Martin Guimond; Matthew P Strout; Brian Becknell; Adrienne Dorrance; Rebecca B Klisovic; Christoph Plass; Clara D Bloomfield; Guido Marcucci; Michael A Caligiuri
Journal:  Blood       Date:  2005-03-17       Impact factor: 22.113

6.  Activator protein-2α functions as a master regulator of multiple transcription factors in the mouse liver.

Authors:  Qingjie Li; Cunhui Luo; Christiane V Löhr; Roderick H Dashwood
Journal:  Hepatol Res       Date:  2011-06-17       Impact factor: 4.288

7.  Genetic and epigenetic silencing of the beclin 1 gene in sporadic breast tumors.

Authors:  Zidong Li; Bo Chen; Yiqing Wu; Feng Jin; Yongjing Xia; Xiangjun Liu
Journal:  BMC Cancer       Date:  2010-03-16       Impact factor: 4.430

8.  Transcription factor activating protein 2 beta (TFAP2B) mediates noradrenergic neuronal differentiation in neuroblastoma.

Authors:  Fakhera Ikram; Sandra Ackermann; Yvonne Kahlert; Ruth Volland; Frederik Roels; Anne Engesser; Falk Hertwig; Hayriye Kocak; Barbara Hero; Daniel Dreidax; Kai-Oliver Henrich; Frank Berthold; Peter Nürnberg; Frank Westermann; Matthias Fischer
Journal:  Mol Oncol       Date:  2015-11-07       Impact factor: 6.603

9.  n-Butylidenephthalide induced apoptosis in the A549 human lung adenocarcinoma cell line by coupled down-regulation of AP-2alpha and telomerase activity.

Authors:  Chyou-wei Wei; Chai-ching Lin; Yung-luen Yu; Chai-yi Lin; Po-cheng Lin; Min-tze Wu; Cheng-jueng Chen; Wenliang Chang; Shinn-zong Lin; Yi-lin Sophia Chen; Horng-jyh Harn
Journal:  Acta Pharmacol Sin       Date:  2009-08-24       Impact factor: 6.150

10.  Selection against PUMA gene expression in Myc-driven B-cell lymphomagenesis.

Authors:  Sean P Garrison; John R Jeffers; Chunying Yang; Jonas A Nilsson; Mark A Hall; Jerold E Rehg; Wen Yue; Jian Yu; Lin Zhang; Mihaela Onciu; Jeffery T Sample; John L Cleveland; Gerard P Zambetti
Journal:  Mol Cell Biol       Date:  2008-06-23       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.